Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes
Authors:
Open Access
- 10 July 2012
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 14 (10) , 944-950
Abstract
Aims: Insulin degludec ( IDeg ) is a new‐generation, ultra‐long‐acting basal insulin that forms soluble multihexamers upon subcutaneous injection, resulting in a depot from which IDeg is absorbed slowly and continuously into circulation. This double‐blind, two‐period, incomplete block cross‐over trial investigated the pharmacodynamic and pharmacokinetic properties of IDeg at steady state ( SS ) in people with type 2 diabetes. Methods: Forty‐nine subjects treated with insulin without concomitant oral anti‐diabetic drugs were given IDeg (0.4, 0.6 and/or 0.8 U/kg) once daily for two 6‐day periods, separated by an interval of 13–21 days. Following dosing on Day 6, subjects underwent a 26‐h euglycaemic glucose clamp (Biostator®; clamp blood glucose level: 90 mg/dl; 5.0 mmol/l). Pharmacokinetic samples were taken until 120 h after last dosing. Results: For all dose levels, the mean glucose infusion rate ( GIR ) profiles were flat and stable. The glucose‐lowering effect of IDeg was evenly distributed over the dosing interval τ, with area under the curve ( AUC ) for each of the four 6‐h intervals being approximately 25% of the total AUC ( AUC GIR ,τ, SS ). Total glucose‐lowering effect increased linearly with increasing dose. The blood glucose levels of all subjects stayed very close to the clamp target until end of clamp. The terminal half‐life of IDeg was approximately 25 h at steady state. IDeg was well tolerated and no safety concerns were identified. No injection site reactions were reported. Conclusions: IDeg has a flat and consistent glucose‐lowering effect in people with type 2 diabetes.Keywords
This publication has 16 references indexed in Scilit:
- Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetesDiabetes, Obesity and Metabolism, 2012
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trialThe Lancet, 2012
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trialThe Lancet, 2012
- Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trialThe Lancet, 2011
- Dose-Response Effects of Insulin Glargine in Type 2 DiabetesDiabetes Care, 2010
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Towards peakless, reproducible and long‐acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studiesDiabetes, Obesity and Metabolism, 2007
- Pharmacokinetics and Pharmacodynamics of the Long-Acting Insulin Analog Glargine After 1 Week of Use Compared With Its First Administration in Subjects With Type 1 DiabetesDiabetes Care, 2007
- Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetesDiabetes, Obesity and Metabolism, 2006
- Insulin detemir under steady‐state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetesDiabetic Medicine, 2006